Cardinal Health (CAH)
(Delayed Data from NYSE)
$93.74 USD
-0.36 (-0.38%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $93.76 +0.02 (0.02%) 4:46 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.74 USD
-0.36 (-0.38%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $93.76 +0.02 (0.02%) 4:46 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q1 Earnings
by Zacks Equity Research
The growing adoption of Panther instruments worldwide will likely drive Hologic's (HOLX) Q1 revenues.
Intuitive Surgical (ISRG) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.
ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues
by Zacks Equity Research
ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Cardinal Health (CAH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $76.47 in the latest trading session, marking a +0.07% move from the prior day.
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome
by Zacks Equity Research
Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) increased shipments in Invisalign case volumes across almost all markets are likely to benefit Q4 revenues.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI), owing to its strong product portfolio.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the increasing adoption of the da Vinci Surgical System. Improving margins buoy optimism.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
BD's (BDX) New Robotic Track System to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing adoption of Panther instruments and growth in the Surgical business will likely drive Hologic's (HOLX) Q1 revenues.
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology
by Zacks Equity Research
Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.
Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues
by Zacks Equity Research
Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Inogen (INGN) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.
Cardinal Health (CAH) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $76.52 in the latest trading session, marking no change from the prior day.
PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.
Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.
Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.